Berenberg initiated coverage of Atai Life Sciences (ATAI) with a Positive rating. Atai has an “exciting” portfolio of psychedelic drug candidates that offer a novel approach to treating mental health disorders with high unmet need and large addressable populations, the analyst tells investors in a research note. The firm says success for just one candidate could offer significant upside to the company’s current market cap.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Biotech Alert: Searches spiking for these stocks today
- Psychedelic: Exclusive talk with retreat provider ONE Retreats
- ATAI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Psychedelic: Exclusive talk with biotech company Clearmind Medicine
- Psychedelic: atai Life Sciences, NRx report quarterly results